Opiant Pharmaceuticals (OPNT) Posts Wider Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts OPNT Hot Sheet
Price: $20.65 --0%
Financial Fact:
Income before provision for income taxes: 6.13M
Today's EPS Names:
JBLU, SICP, OMID, More
Financial Fact:
Income before provision for income taxes: 6.13M
Today's EPS Names:
JBLU, SICP, OMID, More
Join SI Premium – FREE
Opiant Pharmaceuticals (NASDAQ: OPNT) reported Q1 EPS of ($2.43), $1.52 worse than the analyst estimate of ($0.91). Revenue for the quarter came in at $4.5 million versus the consensus estimate of $5.9 million.
For earnings history and earnings-related data on Opiant Pharmaceuticals (OPNT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JetBlue Airways (JBLU) Misses Q3 EPS by 6c, Misses on Revenue
- Northeast Bancorp (NBN) Tops Q3 EPS by 1c
- Avidbank Holdings, Inc. (AVBH) Tops Q3 EPS by 7c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
